Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723223 | 1.00 | FUCA1 (0.53) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL24893928 | 0.89 | FUCA1 (0.46) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL20875293 | 0.85 | FUCA1 (0.46) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL19023831 | 0.85 | FUCA1 (0.46) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL19023830 | 0.85 | FUCA1 (0.46) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL16775256 | 0.84 | FUCA1 (0.64) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL16759827 | 0.84 | FUCA1 (0.64) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL8221734 | 0.83 | FUCA1 (0.55) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL19023828 | 0.83 | FUCA1 (0.55) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL19023829 | 0.83 | FUCA1 (0.55) | FUCA1SIGMAR1ACHEMC4RS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | FUCA1 2760/4885SIGMAR1 3467/4885ACHE 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.